MedPath

Filgotinib

Generic Name
Filgotinib
Brand Names
Jyseleca
Drug Type
Small Molecule
Chemical Formula
C21H23N5O3S
CAS Number
1206161-97-8
Unique Ingredient Identifier
3XVL385Q0M
Background

Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases. The disease is associated with extra-articular manifestations, progressive disability, and comorbidities including cardiovascular disease and mental disorders. 50-70% of patients with RA are unable to achieve sustained clinical remission despite the availability of several treatments including disease-modifying anti-rheumatic drugs (DMARDS) like methotrexate, interleukin-6 (IL-6) blockers, and tumor necrosis factor (TNF) inhibitors. New therapeutic developments target other inflammatory pathways implicated in RA including the Janus kinase (JAK) signaling pathway as seen with filgotinib.

There are four JAK subtypes which include JAK1, JAK2, JAK3, and tyrosine kinase 2. Non-selective JAK inhibitors like tofacitinib target JAK1 and JAK3 subtypes with minimal activity at JAK2. In contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor. JAK2 and JAK3 play important roles in both immune and hematologic functions; therefore, selectivity for JAK1 aims to improve the safety profile of filgotinib while maintaining clinical efficacy. Filgotinib is currently reserved for patients who cannot tolerate DMARDs, or who have been unable to achieve remission in response to one or more DMARDs.

Indication

Filgotinib is indicated for the treatment of active moderate to severe rheumatoid arthritis alone or in combination with methotrexate. Filgotinib is currently reserved for patients who are unable to tolerate or who have not responded adequately to one or more disease-modifying anti-rheumatic drugs (DMARDS).

Filgotinib is also indicated for treatment of moderately to severely active ulcerative colitis in adult patients who had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

Associated Conditions
Active, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Ulcerative Colitis
Associated Therapies
-
biospace.com
·

Galapagos to Spin Out Innovative Medicines, Regain Gilead Assets

Galapagos splits into two entities: one for innovative medicine focusing on oncology, immunology, virology, and another for cell therapies. It regains pipeline rights from Gilead, cuts 40% of its workforce, and plans strategic realignment, aiming for sustainable growth and value creation.
pharmaphorum.com
·

Alfasigma to buy Galapagos' JAK drug for up to €170m

Galapagos sells Jyseleca rights to Alfasigma for up to €170M plus royalties, transferring EU/UK marketing and 400 employees. Jyseleca, once a potential blockbuster, faced FDA rejection and setbacks, leading to reduced sales forecasts. The deal boosts Galapagos' cash and cost-cutting efforts, while Alfasigma expands internationally.
labiotech.eu
·

JAK inhibitors: Are they a good option for treating inflammatory diseases and cancer?

JAK inhibitors are key drugs for treating inflammatory diseases and cancer, with billions in revenue. They target JAK enzymes, crucial for cytokine signaling, reducing inflammation and symptoms. Approved for atopic dermatitis, ulcerative colitis, rheumatoid arthritis, psoriasis, and alopecia areata, they offer significant benefits. For cancer, they treat myelofibrosis and are being explored in combinations with immune checkpoint inhibitors. Safety concerns led to FDA and EMA restrictions, but market growth is expected due to rising autoimmune disease prevalence.
born2invest.com
·

Alfasigma Receives Green Light to Sell Jyseleca in Europe

Alfasigma to market Jyseleca in Europe after acquiring it from Galapagos for €170 million. The drug, a JAK1 inhibitor, is approved for rheumatoid arthritis and ulcerative colitis.
© Copyright 2025. All Rights Reserved by MedPath